Could freezing tumors plus chemo slow prostate cancer spread?
NCT ID NCT06854250
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding prostate cryoablation (freezing the tumor) and a low-dose chemotherapy drug (cyclophosphamide) to standard hormone therapy can delay cancer progression in men with newly diagnosed metastatic prostate cancer. About 104 men aged 18-80 will receive the combination treatment and be monitored for side effects and progression. The goal is to see if this approach works better than hormone therapy alone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510062, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a blast of testosterone shrink hard-to-treat prostate cancer?
- A PET scan and a blood test may predict which men with advanced prostate cancer will benefit from targeted therapy
- New drug ORIC-944 targets Hard-to-Treat prostate cancer
- Precision radiotherapy may buy time for men with spreading prostate cancer
- Mapping Cancer's next move: study tracks where prostate cancer returns after aggressive radiotherapy
- Smart scans may slash radiation doses for metastatic prostate cancer